Company
Headquarters: Taipei, Taiwan
CEO: Mr. Ko-Chung Lin Ph.D.
TW$118.17 Billion
TWD as of Jan. 1, 2024
US$3.85 Billion
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $622.07 B |
Vertex Pharmaceuticals Incorporated | $121.36 B |
Regeneron Pharmaceuticals, Inc. | $115.11 B |
CSL Limited | $95.75 B |
Marinomed Biotech AG | $75.67 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
PharmaEssentia Corporation engages in the research, development, production, and sale of therapeutic products for the treatment of human diseases. Its products include BESREMi (ropeginterferon alfa-2b) that is used for the treatment of polycythemia vera, essential thrombocythemia, and hepatitis B and C; and Anti-PD-1 antibody for the treatment of cancer. The company also licensed to develop Oraxol for the treatment of breast, advanced gastric, and esophageal cancer; and KX01 for the treatment of psoriasis and actinic keratosis. It also focuses on the drug research and development programs in the areas of hematology, infectious disease, oncology, and dermatology. The company sold its products in Germany, Austria, the United Kingdom, France, Denmark, the Czech Republic, and Sweden. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
PharmaEssentia Corp has the following listings and related stock indices.
Stock: TWSE: 6446 wb_incandescent